Wearable Continuous Blood Pressure Monitoring Ring BloodRing Receives FDA Approval: Replacing Traditional Cuff Blood Pressure Monitors
BloodRing uses fingertip photoplethysmography sensors and AI algorithms for cuffless continuous blood pressure monitoring with medical-grade accuracy, receiving FDA Class II medical device clearance.
California health tech company BloodRing announced on February 26 that its namesake wearable blood pressure monitoring device has received FDA Class II medical device clearance. BloodRing is a titanium alloy ring that uses multi-wavelength photoplethysmography sensors and pulse wave velocity analysis at the fingertip to achieve 24-hour continuous cuffless blood pressure monitoring.
In clinical validation involving 1,200 subjects, BloodRing's systolic blood pressure measurement error within ±5mmHg was 91%, and diastolic was 89%, meeting the AAMI/ISO 81060-2 medical standard. The device weighs just 6 grams with 5-day battery life.
BloodRing retails for $299, with a companion app generating blood pressure trend reports and setting abnormal alerts.
Disclaimer
Content is AI-generated. Do not use it as a basis for real decisions. Do not cite it as factual reporting.